Kite Acquires Interius BioTherapeutics to Advance In Vivo Platform
Kite Pharma, a wholly owned subsidiary of Gilead Sciences, announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics for a total of $350 million in cash consideration. Interius BioTherapeutics is a clinical-stage biotechnology company engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases in oncology, autoimmunity and beyond. Leveraging a proprietary platform, Interius has created a differentiated off-the-shelf therapeutic modality designed for broad patient access. The company’s lead programs aim to overcome the current limitations of ex vivo chimeric antigen receptor (CAR)... Read More »
Concentra Biosciences Acquires iTeos Therapeutics for $434 Million
Concentra Biosciences, LLC announced that it entered into an agreement to acquire iTeos Therapeutics for more than $434.4 million. iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. According to iTeos Therapeutics’ financial reports, the company reported $35 million in revenue for the full year 2024. Concentra Biosciences is owned by Tang Capital... Read More »
Supernus Pharmaceuticals to Acquire Sage Therapeutics for $561 Million
Supernus Pharmaceuticals announced on June 16 that it has entered into an agreement to acquire Sage Therapeutics, based in Cambridge, Massachusetts. Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), plus one non-tradable contingent value right (CRV) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million). The total consideration is $12.00 per share in cash (or an aggregate of up to approximately $795 million). The CVR is payable upon achieving certain net sales and commercial milestones. Sage Therapeutics is a biopharmaceutical company committed to developing... Read More »
InformedDNA Acquires Coriell Life Sciences
On May 19, InformedDNA announced that it entered into an agreement to acquire Coriell Life Sciences (CLS), based in Philadelphia, Pennsylvania. According to data captured in the LevinPro HC database, this transaction marks the 54th Biotechnology transaction of the year. CLS is a biotechnology company that provides pharmacogenomic services and clinical decision support. The company delivers DNA testing benefits that empower the most precise medical care, improve population health and reduce healthcare costs. InformedDNA is a leading applied genomics solutions company, helping harness the full power of precision medicine. The company is the preferred provider of genetic counseling... Read More »
Kaixin Pharmaceuticals Acquires CASI Pharmaceuticals Assets for $20 Million
On May 12, Kaixin Pharmaceuticals, Inc. announced that it entered into an agreement to acquire assets of CASI Pharmaceuticals. The purchase price is $20 million, which shall include assumption of up to $20 million of indebtedness of CASI. CASI Pharmaceuticals is a Cayman Island incorporated biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. Kaixin Pharmaceuticals is a Cayman Islands incorporated entity wholly-owned by Dr. Wei-Wu He, Chairman of the board of directors and CEO of CASI Pharmaceuticals and two direct subsidiaries of CASI Pharmaceuticals in China. Under the terms of the agreement, Kaixin... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
